2. Cell Cycle/DNA Damage GPCR/G Protein Apoptosis
  3. Topoisomerase Prostaglandin Receptor Apoptosis
  4. Topo I/COX-2-IN-1

Topo I/COX-2-IN-1 (1H-30) is a potential Topo I/COX-2 inhibitor. Topo I/COX-2-IN-1 inhibits COX-2 and Topo I with the IC50 value of 0.24 μM and 4.42 μM, respectively. Topo I/COX-2-IN-1 can induce apoptosis and inhibit migration of cancer cells, has anti-cancer activity.

For research use only. We do not sell to patients.

Topo I/COX-2-IN-1 Chemical Structure

Topo I/COX-2-IN-1 Chemical Structure

CAS No. : 3031418-84-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Topo I/COX-2-IN-1 Related Antibodies

Top Publications Citing Use of Products

View All Topoisomerase Isoform Specific Products:

View All Isoforms
Topoisomerase Topo I Topo II

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Topo I/COX-2-IN-1 (1H-30) is a potential Topo I/COX-2 inhibitor. Topo I/COX-2-IN-1 inhibits COX-2 and Topo I with the IC50 value of 0.24 μM and 4.42 μM, respectively. Topo I/COX-2-IN-1 can induce apoptosis and inhibit migration of cancer cells, has anti-cancer activity[1].

IC50 & Target[1]

Topoisomerase I

4.42 μM (IC50)

In Vitro

Topo I/COX-2-IN-1 (1H-30) (0-100 μM, 24 h) has anti-tumor cell proliferation activity and can induce apoptosis by increasing caspase-3 activity in a dose-dependent manner[1].
Topo I/COX-2-IN-1 (1H-30) (0.04-0.37 μM, 48 h) shows a significant decrease in cell migration at 0.37 μM and reduces the expression of MMP-9 (matrix metalloproteinases) in HGC-27 and RKO cells[1].
Topo I/COX-2-IN-1 (1H-30) (10 μM, 48 h) can inhibit the activation of NF-κB pathway in cancer cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Topo I/COX-2-IN-1 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: Colon cancer cell lines HGC-27, RKO, HT-29, SGC-7901, and CT26.WT
Concentration: 0-100 μM
Incubation Time:
Result: Inhibited the proliferation of CT26.WT, RKO, HT-29, HGC-27 and SGC-7901 cells with the IC50 values of 3.04, 3.12, 16.93, 4.71 and 14.95 μM, respectively.

Apoptosis Analysis[1]

Cell Line: HGC-27, RKO cell lines
Concentration: 1.1 μM, 3.3 μM, 10 μM
Incubation Time: 24 hours
Result: Increased caspase-3 positive cells to 55.94% and 69.46 % at 10 μM comparing to 1.08% and 9.39% in the untreated group in RKO and HGC-27 cells respectively.

Cell Cycle Analysis[1]

Cell Line: HGC-27, RKO cell lines
Concentration: 1.1 μM, 3.3 μM, 10 μM
Incubation Time:
Result: Induced blocked in G2/M phase significantly.
In Vivo

Topo I/COX-2-IN-1 (1H-30) (intraperitoneal injection, 100 mg/kg, twice a day, 14 days) may inhibit tumor growth by increasing the expression of caspase-3 and decreasing MMP-9 and COX-2 in tumor tissues to induce apoptosis in BALB/c mice model infected with CT26.WT colon cancer cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c mice model infected with CT26.WT colon cancer cells[1]
Dosage: 100 mg/kg
Administration: Intraperitoneal injection; twice a day; 14 days
Result: Significant reduction in tumor size and tumor weight and no significant differences in body weight, organs.
Animal Model: SD rats[1]
Dosage: 100 mg/kg
Administration: Intraperitoneal injection; once
Result: b>The pharmacokinetic parameters of Topo I/COX-2-IN-1 (1H-30)
Parameter Topo I/COX-2-IN-1 (1H-30)
t1/2 1.56 h
Tmax 0.67 h
Cmax 20.19 μg/mL
AUC0-t 18.20 mg/L•h
AUC0‑inf_obs 18.60 mg/L•h
Molecular Weight

400.83

Formula

C21H18ClFN2O3
CAS No.
SMILES

CC1=C(C=CC=C1NC2=CC=C(C=C2C(NCC3=CC=C(C(O)=C3)O)=O)F)Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Topo I/COX-2-IN-1 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Topo I/COX-2-IN-13031418-84-2TopoisomeraseProstaglandin ReceptorApoptosisTopo I/COX-2 inhibitorCOX-2,Topo Ianti-cancermigrationapoptosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Topo I/COX-2-IN-1
Cat. No.:
HY-150685
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.